New bladder cancer drug shows promise in early trial
Disease control
Completed
This early-stage study tested a new drug called UGN-301 (zalifrelimab) in 51 people with recurrent non-muscle invasive bladder cancer. The drug was given directly into the bladder to see if it is safe and to find the best dose. The goal is to control the cancer and prevent it fro…
Phase: PHASE1 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC